Table 4.
Univariate and multivariate analysis for OS and PFS in IDC patients of grade Ⅰ-Ⅱ
| Variable | OS (univariate) |
OS (multivariate) |
PFS (univariate) |
PFS (multivariate) |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | 0.911 (0.385-2.156) | 0.832 | 1.071 (0.430-2.664) | - | 0.676 (0.386-1.187) | 0.173 | 0.759 (0.422-1.367) | - |
| Tumor size | 1.624 (0.740-3.565) | 0.227 | 1.017 (0.456-2.270) | - | 1.852 (1.096-3.130) | 0.021 | 1.139 (0.656-1.976) | - |
| Lymph node metastasis | 1.680 (1.149-2.455) | 0.007 | 1.757 (1.173-2.630) | 0.006 | 1.651 (1.294-2.106) | 0.000 | 1.679 (1.303-2.164) | < 0.001 |
| ER status | 0.766 (0.316-1.857) | 0.556 | 0.436 (0.147-1.295) | - | 0.739 (0.417-1.309) | 0.300 | 0.559 (0.282-1.109) | - |
| PR status | 0.907 (0.366-2.251) | 0.834 | 0.780 (0.277-2.197) | - | 0.645 (0.366-1.137) | 0.129 | 0.498 (0.261-0.950) | - |
| AGR3 expression | 2.695 (1.082-6.713) | 0.033 | 4.161 (1.406-12.312) | 0.010 | 2.531 (1.421-4.511) | 0.002 | 3.856 (1.953-7.613) | < 0.001 |
OS, overall survival; PFS, progression-free survival; IDC, invasive ductal carcinoma; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; AGR3, anterior gradient 3.